Unconventional T cell biologist and genome engineer. Previously @cardiffuni @nyuniversity @nygenome 🏳️🌈
New York, USA
Joined September 2020
- Tweets149
- Following299
- Followers490
- Likes425
Pinned Tweet
After some time in the making, I am really happy to announce @OverT_Bio’s official launch today. I am excited and humbled by the experience of building OverT with a terrific team of scientists and operators #startup #celltherapy #cancer
We're thrilled to launch OverT Bio! Debuting with $16M of initial financing, we will develop safe and effective #celltherapies for solid tumor cancers.
endpts.com/overt-bio-debuts-…
Mat Legut, PhD retweeted
Excited to share a big milestone for OverT Bio—we’ve formed our Clinical Advisory Board.
Grateful to partner with an incredible group of leaders as we build scalable γδ CAR-T therapies for solid tumors.
businesswire.com/news/home/2…
Mat Legut, PhD retweeted
Come and join the extraordinary team of ALLOX and help us accelerate the discovery of more effective therapies!
👉allox.bio/careers
Our team in #Barcelona is expanding & we're #hiring 2 talented scientists to fill these exciting new positions: a Lead Scientist & a Research Associate.
Do u want to make a real difference in the future of applied high-throughput genetics and therapeutics? #PhdChat #ScienceJobs
Mat Legut, PhD retweeted
🎉Congratulations to the team at @OverT_Bio and its co-founders, @MatLegut and former CRI Tech Impact Award Grantee @nevillesanjana on the company's debut! Learn more in @endpts:
We're thrilled to launch OverT Bio! Debuting with $16M of initial financing, we will develop safe and effective #celltherapies for solid tumor cancers.
endpts.com/overt-bio-debuts-…
Mat Legut, PhD retweeted
Congrats to @MatLegut & the entire @OverT_Bio team! Grateful for the opportunity to translate discoveries from our lab @nygenome & @nyuniversity into therapies for cancer patients.
Thrilled to be a part of this amazing team — onward and upward! 🚀
We're thrilled to launch OverT Bio! Debuting with $16M of initial financing, we will develop safe and effective #celltherapies for solid tumor cancers.
endpts.com/overt-bio-debuts-…
Shout-out to my co-founder @nevillesanjana and our partners at @ArtisVentures @Wing_VC @FusionFundVC OMX, Alexandria Venture Investments, @CivilizationVC @GaingelsVC @CancerResearch and Hawktail
Mat Legut, PhD retweeted
We're thrilled to launch OverT Bio! Debuting with $16M of initial financing, we will develop safe and effective #celltherapies for solid tumor cancers.
endpts.com/overt-bio-debuts-…
Mat Legut, PhD retweeted
Big news!! I can finally officially announce that a few weeks ago, ALLOX @ALLOXbio was co-founded by the brilliant André Faure @aj4re , Pablo Baeza @pbcenturion , Ben Lehner @BenLehner , and myself, who will be stepping in as CEO of the company.
Mat Legut, PhD retweeted
Great effort from the team on this study published in Cell today! Hard work pays off - well done everyone 👏🏻
Exciting science - discovering new T-cell receptors for cancer immunotherapies 🔬
#cancerimmunotherpies #cellscience #tcells
cell.com/cell/fulltext/S0092…
Shoutout to @TcellResearch team for this beautiful study! Super happy to have been able to contribute a small part to this work. Hoping this discovery will bring about #tcr #celltherapy to more patients with hard to treat cancers! #immunotherapy
A really exciting article, fresh from the press @CellCellPress! T cells are indeed #crossreactive, in this case a single T cell receptor can bind and recognise distinct cancer antigens from not one, but three proteins (or more!).
authors.elsevier.com/sd/arti…
Mat Legut, PhD retweeted
For anyone interested in our work and our team - we would greatly appreciate extra votes in the following competition! Voting is open until the 4th July 🗳️🙏🏻🧬🧪
MolecularCloud | 2023 Distinguished Research Awards for Gene and Cell Therapy molecularcloud.org/researcha…
Mat Legut, PhD retweeted
I had some fun taking my #ScienceTwitter game to the next level with @WIRED 🐦🎮👨🔬 🙂
And several awesome CRISPR questions too!✂️🧬
Grateful for being invited to participate in the new Tools of the trade series from @NatureRevCancer, highlighting our recent study on developing new #immunotherapy for cancer through genome-scale screens in #tcells
Mat Legut, PhD retweeted
NEW content online! Multiomics-guided cellular immunotherapies dlvr.it/SmTtT9
Great to see we got through the first round! Now let’s go and win the second one!
.@nevillesanjana and colleagues from NYU and @nygenome developed a genetic screening platform to identify genes that transform immune cells into more aggressive cancer fighters. Their promising study was published in @Nature. Vote for it in #statmadness: statnews.com/feature/stat-ma…
ALT researchers working in a lab
Mat Legut, PhD retweeted
.@nevillesanjana and colleagues from NYU and @nygenome developed a genetic screening platform to identify genes that transform immune cells into more aggressive cancer fighters. Their promising study was published in @Nature. Vote for it in #statmadness: statnews.com/feature/stat-ma…
ALT NYU researchers working in a lab
Super excited to see our research on building new immunotherapies getting picked by @statnews to represent @nyuniversity
(Also, turns out this March Madness is like an actual sports thing! Things you learn… 🤷🏻♂️)
statnews.com/feature/stat-ma…
